Lung Cancer EGFR: What Are The Latest Advanced Treatments in 2023? Insights from Ravi Salgia MD - Synopsis below extracted from the video transcript.
Dr. Ravi Salgia provides insights on the latest advanced treatments for lung cancer with EGFR mutations in 2023. He begins by discussing the prevalence of EGFR mutations in lung cancer patients and how these mutations drive the growth and progression of the cancer.
Dr. Salgia then goes on to explain the latest advances in targeted therapies for EGFR-mutated lung cancer. He mentions the use of third-generation EGFR inhibitors, such as osimertinib, which have shown improved efficacy and fewer side effects compared to earlier generations of EGFR inhibitors. He also discusses the use of combination therapies, such as the combination of osimertinib and the MET inhibitor capmatinib, which has shown promising results in clinical trials.
Dr. Salgia further discusses the importance of molecular testing in determining the appropriate treatment for lung cancer patients with EGFR mutations. He emphasizes the need for comprehensive genomic profiling to identify other genetic alterations that may affect treatment decisions.
Read The Full Transcript and Watch The Video Here
In addition to targeted therapies, Dr. Salgia also mentions the role of immunotherapy in the treatment of lung cancer. He explains how immunotherapy works by activating the immune system to attack cancer cells and how it can be used in combination with targeted therapies for EGFR-mutated lung cancer.
Overall, Dr. Salgia provides valuable insights into the latest advanced treatments for lung cancer with EGFR mutations in 2023. He highlights the importance of molecular testing and personalized medicine in determining the most effective treatment approach for each patient. His discussion on the latest advances in targeted therapies and combination therapies provides hope for improved outcomes and quality of life for lung cancer patients.
